# US 2021/0198336 A1 · Il-2r-beta-gamma binding compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0198336 A1
- Document ID: US20210198336A1
- Status: Published application
- Kind: A1
- Application number: 17/089,515
- Filed: 2020-11-04
- Published: 2021-07-01
- Earliest claimed: 2019-11-05
- Assignees: Medikine, Inc.
- Applicants: Medikine, Inc.
- Inventors: WILLIAM J. DOWER; MICHAEL C. NEEDELS; RONALD W. BARRETT; ALICE V. BAKKER; STEVEN E. CWIRLA
- Web page: https://patentgrep.com/patent/US20210198336A1

## CPC

- C07K 14/55: IL-2
- C07K 16/30: from tumour cells
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- C07K 14/7155: {for interleukins [IL]}
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/01: containing a localisation/targetting motif
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/75: containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

IL-2Rβγc binding compounds, and pharmaceutical compositions comprising the IL-2Rβγc binding compounds are disclosed. IL-2Rβγc binding compounds can act as IL-2R agonists and are useful in treating cancer, autoimmune diseases and inflammatory diseases.

## Claims

### Claim 1

An IL-2Rβγc binding compound, wherein the IL-2Rβγc binding compound comprises an IL-2Rβγc ligand, wherein the 2Rβγc ligand comprises:
a ligand linker;
the IL-2Rβ ligand bound to the ligand linker, wherein the IL-2Rβ ligand comprises an amino acid sequence of any one of SEQ ID NOS: 805-903, 911-930, 2575-2655, 2661-2891, 2900-2926, or 2929-2939; and
the IL-2Rγc ligand bound to the ligand linker, wherein the IL-2Rγc ligand comprises an amino acid sequence of any one of SEQ ID NOS: 944-1028, 1032-1060, and 1601-1613.

### Claim 2 (depends on 1)

The IL-2Rβγc binding compound of claim 1, wherein the IL-2Rβ ligand comprises an amino acid sequence of any one of SEQ ID NOS: 911-930, 2929-2939, 9301 and 9308.

### Claim 3 (depends on 1)

The IL-2Rβγc binding compound of claim 1, wherein,
the IL-2Rβ ligand comprises an amino acid sequence having SEQ ID NO: 865; and
the IL-2Rγc ligand comprises an amino acid sequence having SEQ ID NO: 965.

### Claim 4 (depends on 1)

The IL-2Rβγc binding compound of claim 1, wherein the IL-2Rβγc ligand comprises a disulfide bond between two cysteines of the IL-2Rβγc ligand.

### Claim 5 (depends on 1)

The IL-2Rβγc binding compound of claim 1, wherein the ligand linker comprises a peptidyl ligand linker.

### Claim 6 (depends on 1)

The IL-2Rβγc binding compound of claim 1, wherein the IL-2Rβγc ligand comprises an amino acid sequence of any one of SEQ ID NOS: 1263-1270, 4070-4085, and 4090 to 4099.

### Claim 7 (depends on 1)

The IL-2Rβγc binding compound of claim 1, wherein the IL-2Rβγc ligand comprises an amino acid sequence having SEQ ID NO: 1263.

### Claim 8 (depends on 1)

The IL-2Rβγc binding compound of claim 1, wherein the IL-2Rβγc ligand is a full IL-2R agonist or a partial IL-2R agonist.

### Claim 9 (depends on 1)

The IL-2Rβγc binding compound of claim 1, wherein,
the IL-2Rβγc ligand exhibits an EC50 for STAT5 phosphorylation in TF-1β cells and/or NK-92 cells of less than 100 μM; and
the IL-2Rβγc ligand binds to hIL-2R with an IC50 less than 100 μM as determined using phage ELISA competition assays.

### Claim 10 (depends on 1)

The IL-2Rβγc binding compound of claim 1, wherein the IL-2Rβγc binding compound comprises a construct partner, wherein the IL-2Rβγc ligand is bound to the construct partner.

### Claim 11 (depends on 10)

The IL-2Rβγc binding compound of claim 10, wherein in the IL-2Rβγc ligand is bound to the construct partner through a construct linker.

### Claim 12 (depends on 11)

The IL-2Rβγc binding compound of claim 11, wherein the construct linker comprises a peptidyl ligand linker.

### Claim 13 (depends on 10)

The IL-2Rβγc binding compound of claim 10, wherein the construct partner is selected from a polymer, a polypeptide, an Fc-fragment, an immunoglobulin fragment, an antibody, a viral surface antigen or a virus-like particle, a cytokine, and a recombinant fusion protein.

### Claim 14 (depends on 10)

The IL-2Rβγc binding compound of claim 10, wherein the IL-2Rβγc binding compound is selected from a polyethylene glycol, a hIgG-Fc recombinant fusion protein, and a hIgG1-Fc recombinant fusion protein.

### Claim 15 (depends on 10)

The IL-2Rβγc binding compound of claim 10, wherein the construct partner comprises an antibody and the antibody is directed to a tumor antigen.

### Claim 16 (depends on 10)

The IL-2Rβγc binding compound of claim 10, wherein the construct partner comprises a cell-targeting moiety.

### Claim 17 (depends on 16)

The IL-2Rβγc binding compound of claim 16, wherein cell-targeting moiety comprises a tumor-targeting moiety, an immune cell-targeting moiety, or a combination thereof.

### Claim 18 (depends on 1)

A pharmaceutical composition comprising the IL-2Rβγc binding compound of claim 1.

### Claim 19 (depends on 1)

A method of treating a disease in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of the IL-2Rβγc binding compound of claim 1, wherein the disease is selected from cancer, an autoimmune disease, an inflammatory disease, an infectious disease, and a viral disease.

### Claim 20 (depends on 18)

A method of treating a disease in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of the pharmaceutical composition of claim 18, wherein the disease is selected from cancer, an autoimmune disease, an inflammatory disease, an infectious disease, and a viral disease.
